Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (CELU) is a clinical-stage biotechnology pioneer developing placental-derived cell therapies targeting cancer, immune disorders, and degenerative diseases. This page serves as the definitive source for verified company announcements and research developments.
Access real-time updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection provides investors with essential updates on Celularity's NK cell therapies, CAR T-cell advancements, and biomaterial innovations while maintaining compliance with financial disclosure standards.
Key updates include earnings reports, manufacturing expansions, intellectual property developments, and peer-reviewed research publications. Bookmark this page for structured access to Celularity's progress in creating off-the-shelf cellular therapies and its bio-banking operations.
Celularity has presented promising in vivo data at the ASCO Annual Meeting showing the potential of its T-cell therapy platform, PT-CD16VS, in targeting multiple hematological and solid tumors. The platform leverages genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells and can be combined with various monoclonal antibodies. Previous data at AACR demonstrated efficacy against HER2-positive cancers, and the recent findings extend this potential to a broader range of cancers. The company is also expanding its pipeline to tackle aging-related healthcare issues such as cellular senescence.
Celularity (Nasdaq: CELU), a regenerative medicine company, received a Nasdaq notice on May 21, 2024, for not filing its Q1 2024 Form 10-Q and 2023 Form 10-K on time. This puts Celularity in non-compliance with Nasdaq's listing requirements, but it doesn't affect the current trading of its stock and warrants. Celularity must submit a compliance plan by June 17, 2024, and has until October 14, 2024, to regain compliance if the plan is accepted. The company is working to complete its filings but cannot guarantee Nasdaq will accept the plan or that it will meet future requirements.
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to those derived from adult peripheral blood mononuclear cells (PBMCs). Key findings include longer telomeres and attenuated cytokine responses without loss of cytotoxicity. These advantages may lead to more effective and scalable CAR-T therapies. Dr. Robert Hariri, CEO of Celularity, emphasized the potential of their platform to deliver improved and durable allogeneic CAR-T products.
FAQ
What is the current stock price of Celularity (CELU)?
What is the market cap of Celularity (CELU)?
